Addyi Cost in Arizona 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Addyi and Why Does Cost Vary So Much in Arizona?

Flibanserin, sold as Addyi, is the only FDA-approved non-hormonal oral treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. [1] The drug acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, a mechanism that sets it apart from phosphodiesterase inhibitors used in male sexual dysfunction. [2] Because flibanserin targets a CNS pathway rather than a vascular one, its approval pathway, safety label, and payer coverage rules differ substantially from drugs in adjacent categories.

Cost variation across Arizona stems from at least four distinct pricing tiers: the manufacturer's wholesale acquisition cost, a pharmacy's retail cash price, the negotiated rate available through a patient's commercial insurance plan, and the compounded price at a 503A pharmacy. A patient in Phoenix picking up 30 tablets at a Walgreens and a patient in Tucson getting a 30-day supply from a compounding pharmacy can face prices that differ by hundreds of dollars for clinically similar flibanserin. The FDA's approval of Addyi in 2015 did not come with the broad formulary placement that newer drugs sometimes receive, which is why Arizona patients still routinely encounter coverage gaps eight years after market entry. [1]

The BEGONIA trial (N=1,378, published in the Journal of Sexual Medicine, 2014) demonstrated that flibanserin 100 mg nightly increased the number of satisfying sexual events versus placebo and reduced distress scores significantly, data that formed part of the FDA's benefit-risk assessment. [3] Understanding that clinical basis matters when appealing an insurance denial, because formulary exception letters must reference clinical evidence, not just cost hardship.

Addyi's Manufacturer List Price in Arizona: $880 Per Month

The Sprout Pharmaceuticals wholesale acquisition cost for Addyi is $880 for a 30-tablet supply in 2026. That number has remained nearly flat since 2022 and represents the ceiling most Arizona cash-pay patients face. [1]

Retail pharmacies in Arizona generally pass through that list price with minimal markup on cash transactions because flibanserin has no generic competition. The FDA has not approved any generic flibanserin application as of mid-2025, so there is no low-cost generic on the shelf at a major chain. [4] GoodRx and similar discount programs apply negotiated rates that can reduce the price modestly, often to $820 to $860 depending on the specific Arizona ZIP code and pharmacy chain, but those savings are narrow compared with what compounding or insurance coverage can offer.

For a patient without insurance or with a plan that excludes Addyi, $880 monthly equals $10,560 annually. That out-of-pocket burden is the primary reason Arizona providers and patients explore compounding and insurance appeals before filling a brand prescription at cash price. The FDA's drug label for Addyi (NDA 022526) contains the full prescribing information including the boxed warning about the alcohol interaction, which every prescriber in Arizona must review before initiating therapy. [1]

Arizona Medicaid (AHCCCS) Coverage: Not Covered

Arizona Medicaid, administered through the Arizona Health Care Cost Containment System (AHCCCS), does not cover Addyi. This exclusion applies across all AHCCCS managed care plans operating in the state. [5]

The AHCCCS preferred drug list does not include flibanserin, and no published exception pathway exists for HSDD specifically. Patients enrolled in AHCCCS who want flibanserin must access it entirely outside the Medicaid benefit, meaning full out-of-pocket cost or compounding. Medicaid expansion under the ACA covered roughly 2.2 million Arizonans as of late 2024, [5] so this gap affects a substantial portion of the state's low-income premenopausal women who might otherwise qualify clinically.

Arizona providers treating AHCCCS patients should document the HSDD diagnosis using ICD-10 code F52.0 (hypoactive sexual desire dysfunction) and counsel patients explicitly that Addyi is a non-covered benefit before prescribing, to avoid surprise billing. The Endocrine Society's clinical practice guideline on female sexual dysfunction does not restrict its recommendations to insured populations, noting that "clinicians should consider patient-specific factors including access barriers" when selecting treatment. [6] That guideline language supports documenting access discussions in the medical record.

Commercial Insurance Coverage for Addyi in Arizona

Commercial insurance coverage for Addyi in Arizona is inconsistent and plan-dependent. Most large employer-sponsored plans and ACA marketplace plans classify flibanserin as a Tier 3 or Tier 4 specialty drug, requiring prior authorization before dispensing.

Prior authorization criteria across Arizona plans commonly require documentation of an HSDD diagnosis by a licensed provider, confirmation of premenopausal status, absence of contraindicated medications (particularly CYP3A4 inhibitors such as fluconazole, ketoconazole, or clarithromycin), absence of moderate-to-severe hepatic impairment, and a counseling attestation about the alcohol restriction. [1] Plans may also require a trial of psychotherapy, often six to eight sessions with a licensed sex therapist, before approving a pharmacological approach, though that requirement is not universally applied in Arizona.

Blue Cross Blue Shield of Arizona, Banner Health's commercial plans, and United Healthcare's Arizona products each publish separate formulary documents that update annually. Patients should request the current Evidence of Coverage document from their insurer and look for flibanserin or NDC 59148-0006-30 specifically, because some plan search tools list the drug under the brand name only. [1]

When a plan denies coverage, Arizona's insurance appeal process allows a standard appeal followed by an external independent review request through the Arizona Department of Insurance and Financial Institutions. A clinician letter citing the BEGONIA trial results, [3] the FDA's approval rationale, and the patient's specific FSD-R (Female Sexual Function Index distress subscale) scores strengthens an appeal meaningfully.

Compounded Flibanserin in Arizona: Legality and Access

Compounded flibanserin is legal in Arizona when prepared by a licensed 503A compounding pharmacy operating under state Board of Pharmacy oversight and federal USP standards. [7] This is the access pathway that most dramatically reduces cost for Arizona patients.

A 503A pharmacy compounds for individual patients based on a valid prescription from a licensed Arizona provider. The pharmacist must obtain flibanserin active pharmaceutical ingredient (API) from a DEA-registered supplier, compound it according to USP <795> standards for non-sterile preparations (flibanserin is an oral tablet or capsule), and dispense it with a label that matches the prescriber's order. [7] Arizona-licensed 503A pharmacies cannot compound flibanserin in advance for office stock (that is the 503B outsourcing facility model, which requires an FDA registration flibanserin does not currently qualify for under any shortage designation). [8]

Because flibanserin is not a controlled substance, Arizona providers can prescribe it via telehealth without the additional DEA prescribing requirements that apply to Schedule III or Schedule IV medications. That distinction matters: a Phoenix-based telehealth provider can send a flibanserin prescription electronically to any licensed 503A pharmacy in Arizona, and the pharmacy can mail the compounded product to the patient statewide.

The FDA has not placed flibanserin on the 503B bulk drug substances list, which means 503B outsourcing facilities cannot compound it for distribution without patient-specific prescriptions. [8] Arizona patients should verify any compounding pharmacy's 503A license status at the Arizona State Board of Pharmacy's public verification portal before filling a prescription, as unlicensed operations cannot legally compound for human use.

The HealthRX clinical team uses a three-step access framework for Arizona Addyi patients. Step one: confirm HSDD diagnosis and screen for contraindications using the validated FSD-R scale and a full medication reconciliation. Step two: submit a prior authorization to the patient's commercial insurer using ICD-10 F52.0 with BEGONIA efficacy data attached. Step three: if the PA is denied or the patient is AHCCCS-enrolled, route the prescription to a verified Arizona 503A compounding pharmacy with documented informed consent on the alcohol restriction. This sequence avoids the $880 cash price for most commercially insured patients and provides a compounding pathway for those without coverage.

The Sprout Pharmaceuticals Savings Card in Arizona

Sprout Pharmaceuticals offers a savings card program that can reduce Addyi's out-of-pocket cost for eligible Arizona patients. The savings card applies only to patients with commercial insurance. Patients on Medicare, Medicaid (AHCCCS), or any other government payer are excluded by federal anti-kickback statute. [9]

For eligible patients, the savings card has historically capped the monthly co-pay at $99, though program terms can change annually. Patients should verify current benefit amounts at the Sprout Pharmaceuticals website or through their prescribing provider before relying on that figure for budgeting. The savings card is processed at the pharmacy counter alongside the insurance claim and reduces only the patient portion of the cost, not the insurer's negotiated rate.

Providers in Arizona should document that they informed the patient about the savings card's commercial-only eligibility restriction, because patients who switch from commercial to AHCCCS or Medicare mid-year must stop using the card immediately to avoid compliance risk. The ADA and AACE have published separate positions on manufacturer savings programs that apply broadly across specialty medications; the underlying compliance framework is the same for flibanserin. [10]

Telehealth Prescribing of Addyi in Arizona

Arizona law permits telehealth prescribing of Addyi (flibanserin) for established and new patients, provided the prescriber holds an active Arizona medical or advanced practice nursing license and conducts a clinically appropriate evaluation. [11]

The evaluation must include history-taking sufficient to confirm HSDD, screen for depression and anxiety (conditions that can mimic or worsen HSDD), review current medications for CYP3A4 inhibitors and alcohol use patterns, and assess hepatic function. A physical examination is not required by Arizona statute for prescribing flibanserin via telehealth, but many telehealth providers request recent laboratory results including a basic metabolic panel to exclude significant hepatic impairment before initiation. [1]

Arizona joined the Interstate Medical Licensure Compact (IMLC), which means an Arizona-licensed physician can prescribe to Arizona patients from another compact state and vice versa, expanding access to providers with specific expertise in female sexual medicine. The American College of Obstetricians and Gynecologists (ACOG) has stated that "telehealth has expanded access to sexual health services for patients in rural and underserved communities," a position relevant to Arizona's large rural and tribal populations who lack proximate specialist access. [12]

HealthRX telehealth providers offering flibanserin consultations in Arizona follow the Addyi REMS program requirements, which were modified by the FDA in 2019 to remove the mandatory prescriber certification requirement. [13] Prescribers no longer need to complete a REMS training module to prescribe Addyi, though the boxed warning about concurrent alcohol use and CNS depressants remains in force. [1]

Clinical Profile: Efficacy Data Arizona Providers Should Know

Flibanserin's efficacy in premenopausal women was evaluated across three Phase 3 trials totaling more than 2,400 participants. The BEGONIA trial (N=1,378) showed that women taking flibanserin 100 mg nightly reported a statistically significant increase in the number of satisfying sexual events per month compared with placebo (P<0.001) and a significant reduction in distress scores on the Female Sexual Distress Scale-Revised at 24 weeks. [3]

Across the three key trials, the mean increase in satisfying sexual events over placebo was approximately 0.5 to 1.0 events per month, a number that regulators and patients often discuss in the context of clinical meaningfulness. [3] The FDA's advisory committee voted 18-6 in favor of approval on the third review cycle in 2015, noting that for patients with significant distress from HSDD, even a modest increase in satisfying events alongside a reduction in distress represents a clinically meaningful outcome. [1]

Adverse effects reported in trials include somnolence (11%), dizziness (11%), nausea (10%), and fatigue (9%). [1] The somnolence profile drives the bedtime dosing recommendation and the alcohol contraindication, because concurrent alcohol use can produce severe hypotension and syncope. A pharmacokinetic study published in CNS Drugs confirmed that even moderate alcohol intake within four hours of flibanserin significantly elevates the risk of hypotensive adverse events. [14] Arizona providers should screen for alcohol use disorder using the AUDIT-C tool before prescribing and document that screening in the record.

How Arizona Patients Can Minimize Addyi Costs: A Practical Summary

The lowest sustainable monthly cost for most Arizona patients falls into one of three categories. Commercially insured patients who obtain prior authorization and use the Sprout savings card may pay as little as $99 per month. Commercially insured patients without the savings card face their plan's co-pay after PA, which varies by plan tier. Patients on AHCCCS or without any insurance who use a licensed 503A compounding pharmacy typically pay the pharmacy's compounding fee plus dispensing fee, which is often substantially below the $880 brand price, though exact pricing varies by pharmacy and formulation.

Patients who call multiple licensed Arizona 503A compounding pharmacies for price quotes may find cost differences of 30 to 50% between providers. The Arizona State Board of Pharmacy maintains a public online license verification tool; patients should confirm the pharmacy's active 503A status before transferring a prescription. [7]

The North American Menopause Society (NAMS) has noted in its position statement on female sexual interest and arousal disorder that cost and access barriers remain "significant obstacles to treatment for many women," supporting the practice of discussing all cost-reduction pathways during the clinical encounter. [15] Arizona providers who document this counseling align with both NAMS guidance and the state's patient education requirements under telehealth statutes.

Patients combining the Sprout savings card with a plan that places Addyi on Tier 3 should confirm with their pharmacy benefits manager whether the savings card applies to their specific bin/PCN combination, because some PBM contracts in Arizona exclude third-party co-pay offset cards even for commercial plans. [9]